Risperidone-induced Somnambulism: A Case Report and Brief Review of Literature

Ahmad Najmi 1, Faisal Siddiqui 2, Avik Ray 1, Ratinder Jhaj 1, Balakrishnan Sadasivam 1

1. Department of Pharmacology, All India Institute of Medical Sciences Bhopal, Bhopal, IND
2. Department of Psychiatry, All India Institute of Medical Sciences Bhopal, Bhopal, IND

Corresponding author: Avik Ray, avik.jrpharma18@aiimsbhopal.edu.in

Abstract

Atypical antipsychotic drugs have been recommended as the first-line agents in the treatment of schizophrenia. They are usually not associated with extrapyramidal symptoms and hyperprolactinemia. There is no previously reported case on somnambulism associated with risperidone intake. We report a case of risperidone-induced somnambulism in a schizophrenic patient. Somnambulism occurred while the patient was on a dose of 3 mg of risperidone per day. The dose was reduced to 2 mg per day along with the addition of clonazepam 0.5 mg daily at night. No further episode of somnambulism was reported after this. This case suggests the association of risperidone with occurrence of somnambulism. Further evidence to strengthen the causality of this needs to be gathered. This calls for prompt pharmacovigilance reporting of adverse drug events associated especially with antipsychotics.

Introduction

Atypical antipsychotic drugs have been recommended as the first-line agents in the treatment of schizophrenia [1]. While these agents do not entirely rule out the risks of extrapyramidal symptoms and hyperprolactinemia, the incidence is greatly reduced when administered in therapeutic ranges [2]. Somnambulism, a type of parasomnia, is characterized by a group of unwanted movements in bed during sleep or even sleepwalking. It mainly occurs in children aged four to eight years and disappears as they approach their teenage [3]. Risperidone is a potent atypical antipsychotic and acts as an antagonist/inverse agonist at serotonergic (5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2C, 5-HT3A, 5-HT3B), dopaminergic (D1-5), adrenergic (α1A, α2A-2C) and histaminergic (H1, H2) receptors, lacking any effect on the muscarinic receptors [4]. Several studies have reported drug-induced sleepwalking in the past decade involving zolpidem, olanzapine, quetiapine, lithium and propranolol [5-8]. However, after thorough literature search, no previously reported case on somnambulism associated with risperidone administration could be found. We report a case of risperidone-induced somnambulism in a patient with schizophrenia.

Case Presentation

The patient was a 38-year-old male who had symptoms of second-order hallucinations, delusion of reference, muttering, impaired biological functions and socio-occupational dysfunction for three months. He was diagnosed with schizophrenia according to International Statistical Classification of Diseases and Related Health Problems (ICD)-10 criteria by a licensed psychiatrist and underwent treatment with an atypical antipsychotic drug, risperidone...
at a dose of 2 mg per day initially which was gradually titrated to 6 mg per day within three months. The patient came for monthly follow-ups. He attained remission within six months of treatment, and the dose of risperidone was reduced to 3 mg per day on which he was well maintained and the symptoms of schizophrenia did not re-appear. After one year of remission, the patient’s wife reported about a few episodes of sleepwalking with open eyes and loud talking. She mentioned that the patient had been relocating his clothes and personal belongings in his room, while he had not been able to reply to his wife. He had got back to bed and continued sleeping, while having no memory of the event the next day. He had no delusions and hallucinations, and he was relatively functional.

The patient had no personal or family history of somnambulism. He did not have any history of alcohol intake, use of nicotine or any other substance abuse. He was prescribed clonazepam 0.5 mg per night, and risperidone was continued at a reduced dose of 2 mg daily. On his next monthly visit, no episode of somnambulism was reported by his wife and no similar symptoms were reported after three months of follow-up.

**Discussion**

Somnambulism occurs during the period of slow wave sleep (stages 3 and 4) due to impairment in the normal mechanisms of arousal from sleep, leading to abnormal motor behaviors without complete awareness [9]. Atypical antipsychotics, such as olanzapine and risperidone, may enhance the slow wave sleep by blocking 5-HT2C receptors, leading to various parasomnias [10]. While two cases of pavor nocturnus (night terror) due to single nightly dose of risperidone have been reported, low-dose risperidone at 2 mg daily has been used to successfully treat cases of night terrors and sleepwalking in adults [11-13]. Enhancement in the slow wave sleep due to risperidone was thought to be the reason for night terror, and the symptoms disappeared on dividing the drug dose, thus reducing its plasma concentration [11].

Sleepwalking is considered to be on the same nosologic continuum as night terrors. A longitudinal study showed that almost one-third of the children who had experienced early childhood night terrors developed sleepwalking later in their life [14]. Most of the cases of somnambulism in adults are continuation of childhood behavior triggered by a medication or psychopathology [3]. In our case, the patient did not have any personal or family history of parasomnia; this might however be due to recall bias.

Non-antipsychotics such as lithium and beta-blockers and other substances like alcohol, nicotine and opioids can also be associated with somnambulism and other sleep arousal disorders [10]. The patient did not have any history of usage of any such substances. Temporal correlation was established since the episodes of sleepwalking occurred after treatment with risperidone was started. The symptoms completely disappeared after a slight reduction of the dose of risperidone and addition of clonazepam, indicating that risperidone was the causative agent for the condition. Other precipitating factors such as fever, stress and other disorders causing sleep arousals (obstructive sleep apnea, distention of bladder, loud noise) were also ruled out [15].

Using the causality assessment algorithm of Naranjo et al., a total score of 7 was obtained, indicating a probable causative relationship between somnambulism and risperidone [16]. The case was reported to the hospital adverse drug reaction monitoring center.

**Conclusions**

This is the first case of risperidone-induced somnambulism to be reported. Further evidences regarding the range of dose and plasma concentration at which risperidone is associated with somnambulism are needed. Hence, drawing attention of physicians and other health care
professionals to such adverse effects associated especially with antipsychotics and prompt pharmacovigilance reporting are required.

Additional Information

Disclosures

**Human subjects:** Consent was obtained by all participants in this study. Issued approval N/A.

**Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

**Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Hasan A, Falkai P, Wobrock T, et al.: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012, 13:518-378. 10.3109/15622975.2012.696145

2. Kusumi I, Boku S, Takahashi Y: Psychopharmacology of atypical antipsychotic drugs: from the receptor binding profile to neuroprotection and neurogenesis. Psychiatry Clin Neurosci. 2014, 69:245-258. 10.1111/pcn.12242

3. Plante DT, Winkelman JW: Parasomnias: psychiatric considerations. Sleep Med Clin. 2008, 3:217-229. 10.1016/j.jsmc.2008.01.005

4. Chopko TC, Lindsley CW: Classics in chemical neuroscience: risperidone. ACS Chem Neurosci. 2018, 9:1520–1529. 10.1021/acschemneuro.8b00159

5. Sharma A, Dewan VK: A case report of zolpidem-induced somnambulism. Prim Care Companion J Clin Psychiatry. 2007, 9:74. 10.4088/pcc.v07n0207a

6. Faridhosseini F, Zamani A: A case report of somnambulism associated with olanzapine. Iran J Psychiatry Behav Sci. 2012, 6:72-74.

7. Hafeez ZH, Kalinowski CM: Two cases of somnambulism induced by quetiapine. Prim Care Companion J Clin Psychiatry. 2007, 9:313. 10.4088/pcc.v09n0411a

8. Huynh NT, Huot P: Propranolol-induced somnambulism: a case-report in a patient with essential tremor. Can J Neurol Sci. 2014, 41:787–788. 10.1017/cjn.2014.101

9. Avidan AY, Kaplish N: The parasomnias: epidemiology, clinical features and diagnostic approach. Clin Chest Med. 2010, 31:355-370. 10.1016/j.ccm.2010.02.015

10. Monti JM, Monti D: Sleep in schizophrenia patients and the effects of antipsychotic drugs. Sleep Med Rev. 2004, 8:153–148. 10.1016/S1087-0792(02)00158-2

11. Prueter C, Luecke FG, Hoff P: Pavor nocturnus as a side effect of a single daily risperidone dose. Gen Hosp Psychiatry. 2005, 27:298–303. 10.1016/j.genhosppsych.2005.02.007

12. Detweiler MB: Risperidone for night terrors and sleepwalking in an adult: a case report. J Pharm Technol. 2013, 29:143-148.

13. Detweiler MB, Khachiyants N, Ali RM, Kim KY, Detweiler JG: Risperidone for post-traumatic combat nightmares: a report of four cases. Consult Pharm. 2011, 26:920–928. 10.4140/TCP.n.2011.920

14. Petit D, Pennestri MH, Paquet J, et al.: Childhood sleepwalking and sleep terrors: a longitudinal study of prevalence and familial aggregation. JAMA Pediatr. 2015, 169:653–658. 10.1001/jamapediatrics.2015.127

15. Bharadwaj R, Kumar S: Somnambulism: diagnosis and treatment. Indian J Psychiatry. 2007, 49:123–125. 10.4103/0019-5545.33261

16. Naranjo CA, Busto U, Sellers EM, et al.: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239–245. 10.1038/clpt.1981.154